Navigation Links
Cancer research presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/1/2010

SAN ANTONIO More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

The symposium is the largest of its kind anywhere in the world. Each year it draws academicians, clinicians, survivors, patient advocates, industry and others interested in the advancement of breast cancer research to discuss and learn about new and late-breaking research, which includes experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials.

The CTRC-AACR San Antonio Breast Cancer Symposium is a partnership between the Cancer Therapy and Research Center (CTRC) at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine.

"The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer," said Program Chairperson C. Kent Osborne, M.D., director of the Dan L. Duncan Cancer Center at the Baylor College of Medicine. "By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients."

The symposium begins on Wednesday, Dec. 8, with a full schedule of educational events. The opening plenary session begins the next day at 8:30 a.m. CT in Exhibit Hall D of the Henry B. Gonzales Convention Center.

In addition to the ongoing plenary session, there is a full industry exhibit hall and a program for survivors and breast cancer advocates. Press conferences will be held for registered members of the media.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
2. Finger length points to prostate cancer risk
3. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
4. Cancer risk from medical radiation may have been overestimated
5. Annual breast cancer screening beginning at age 40 reduces mastectomy risk
6. Active surveillance for low-risk prostate cancer may offer better quality-of-life
7. Breast Cancer Rates Lower With Less Hormone Therapy: Study
8. Study Backs Active Surveillance for Low-Risk Prostate Cancer
9. Celebrex may help prevent some non-melanoma skin cancers
10. Experimental vaccine sets sights on lung cancer
11. Drop in breast cancer rates directly tied to reduced hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)...  Axovant Sciences Ltd. (NYSE: AXON ... the treatment of dementia, today announced a new ... trial evaluating treatment with intepirdine (RVT-101), combined with ... placebo in people with mild-to-moderate Alzheimer,s disease. This ... treatment was associated with reduced progression in dependence ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
Breaking Medicine Technology: